lenalidomide
Selected indexed studies
- Lenalidomide in follicular lymphoma. (Blood, 2020) [PMID:32236519]
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. (J Clin Oncol, 2020) [PMID:31652094]
- The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. (Science, 2014) [PMID:24292623]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Lenalidomide in follicular lymphoma. (2020) pubmed
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. (2020) pubmed
- The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. (2014) pubmed
- Lenalidomide in DLBCL: are we past the cell of origin? (2021) pubmed
- Lenalidomide: A Review in Previously Treated Follicular Lymphoma. (2020) pubmed
- Lenalidomide. (2014) pubmed
- Lenalidomide for the treatment of mantle cell lymphoma. (2019) pubmed
- A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients. (2025) pubmed
- Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity. (2020) pubmed
- Lenalidomide Desensitization for Delayed Cutaneous Reaction: A Case Series and Review of the Literature. (2023) pubmed